{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:04:14Z","timestamp":1771027454343,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bcp.2019.06.019","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T12:27:02Z","timestamp":1561465622000},"page":"162-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["MicroRNAs change the games in central nervous system pharmacology"],"prefix":"10.1016","volume":"168","author":[{"given":"Davide","family":"Marangon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Raffaele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2012.04.005","article-title":"Roles for microRNAs in conferring robustness to biological processes","volume":"149","author":"Ebert","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2019.06.019_b0015","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/970607","article-title":"Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation","volume":"2014","author":"Valinezhad Orang","year":"2014","journal-title":"Int. J. Genomics"},{"issue":"5","key":"10.1016\/j.bcp.2019.06.019_b0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuron.2010.02.018","article-title":"MicroRNA-mediated control of oligodendrocyte differentiation","volume":"65","author":"Zhao","year":"2010","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0025","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.18632\/oncotarget.2734","article-title":"MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype","volume":"6","author":"Ben-Hamo","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.12.006","article-title":"Transcriptional and epigenetic regulation of human microRNAs","volume":"331","author":"Wang","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1261\/rna.068692.118","article-title":"Post-transcriptional control of miRNA biogenesis","volume":"25","author":"Michlewski","year":"2019","journal-title":"RNA"},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.23880","article-title":"Circulating microRNAs as biomarkers for disease staging in multiple sclerosis","volume":"73","author":"Gandhi","year":"2013","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12974-016-0648-x","article-title":"Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)","volume":"13","author":"Vaknin-Dembinsky","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0050","first-page":"695","article-title":"The emerging role of microRNAs in drug responses","volume":"12","author":"Zhang","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0055","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021287","article-title":"Adult neurogenesis in neurodegenerative diseases","volume":"7","author":"Winner","year":"2015","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038562","article-title":"MiR-34a represses Numbl in murine neural progenitor cells and antagonizes neuronal differentiation","volume":"7","author":"Fineberg","year":"2012","journal-title":"PloS One"},{"issue":"20","key":"10.1016\/j.bcp.2019.06.019_b0065","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/emboj.2011.327","article-title":"microRNA-34c is a novel target to treat dementias","volume":"30","author":"Zovoilis","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2019.06.019_b0070","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nbd.2013.10.026","article-title":"Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy","volume":"62","author":"Gorter","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nsmb.1576","article-title":"A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7359","key":"10.1016\/j.bcp.2019.06.019_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature10323","article-title":"MicroRNA-mediated conversion of human fibroblasts to neurons","volume":"476","author":"Yoo","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0085","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0460.1000420","article-title":"microRNAs in neurodegeneration: current findings and potential impacts","volume":"8","author":"Sharma","year":"2018","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"issue":"33","key":"10.1016\/j.bcp.2019.06.019_b0090","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1523\/JNEUROSCI.0630-16.2016","article-title":"The Brain-Enriched MicroRNA miR-9-3p regulates synaptic plasticity and memory","volume":"36","author":"Sim","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2019.06.019_b0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-9966-32-41","article-title":"Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma","volume":"32","author":"Guo","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"69","key":"10.1016\/j.bcp.2019.06.019_b0100","doi-asserted-by":"crossref","first-page":"114065","DOI":"10.18632\/oncotarget.23119","article-title":"MiR-124 acts as a target for Alzheimer's disease by regulating BACE1","volume":"8","author":"An","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00401-013-1142-5","article-title":"MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation","volume":"126","author":"Doeppner","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuron.2010.01.005","article-title":"Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132","volume":"65","author":"Edbauer","year":"2010","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0115","first-page":"365","article-title":"microRNA (miRNA) speciation in Alzheimer\u2019s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF)","volume":"3","author":"Alexandrov","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0120","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020461","article-title":"Transcriptional and epigenetic regulation of oligodendrocyte development and myelination in the central nervous system","volume":"7","author":"Emery","year":"2015","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.019_b0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuron.2010.01.027","article-title":"Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination","volume":"65","author":"Dugas","year":"2010","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0130","doi-asserted-by":"crossref","first-page":"566e5","DOI":"10.1016\/j.devcel.2017.03.001","article-title":"miR-219 cooperates with miR-338 in myelination and promotes myelin repair in the CNS","volume":"40","author":"Wang","year":"2017","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bcp.2019.06.019_b0135","doi-asserted-by":"crossref","first-page":"41407","DOI":"10.1038\/srep41407","article-title":"Transplanted miR-219-overexpressing oligodendrocyte precursor cells promoted remyelination and improved functional recovery in a chronic demyelinated model","volume":"7","author":"Fan","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2018.11.016","article-title":"Scaffold-mediated sustained, non-viral delivery of miR-219\/miR-338 promotes CNS remyelination","volume":"27","author":"Milbreta","year":"2019","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.bcp.2019.06.019_b0145","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1242\/dev.050633","article-title":"Control of oligodendroglial cell number by the miR-17-92 cluster","volume":"137","author":"Budde","year":"2010","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.bcp.2019.06.019_b0150","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.22090","article-title":"Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination","volume":"68","author":"Harrington","year":"2010","journal-title":"Ann. Neurol."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2019.06.019_b0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1242\/dmm.001065","article-title":"miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination","volume":"2","author":"Lin","year":"2009","journal-title":"Dis. Models Mech."},{"issue":"43","key":"10.1016\/j.bcp.2019.06.019_b0160","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1317182110","article-title":"MicroRNA-23a promotes myelination in the central nervous system","volume":"110","author":"Lin","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2019.06.019_b0165","doi-asserted-by":"crossref","first-page":"34503","DOI":"10.1038\/srep34503","article-title":"MiR-125a-3p timely inhibits oligodendroglial maturation and is pathologically up-regulated in human multiple sclerosis","volume":"6","author":"Lecca","year":"2016","journal-title":"Sci. Rep."},{"issue":"Pt 12","key":"10.1016\/j.bcp.2019.06.019_b0170","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1093\/brain\/awp300","article-title":"MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47","volume":"132","author":"Junker","year":"2009","journal-title":"Brain"},{"issue":"22","key":"10.1016\/j.bcp.2019.06.019_b0175","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1212\/WNL.0b013e3182759621","article-title":"Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study","volume":"79","author":"Haghikia","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2010.179","article-title":"The emerging role of microRNAs in multiple sclerosis","volume":"7","author":"Junker","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12974-017-1006-3","article-title":"Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS","volume":"14","author":"Bruinsma","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000219","article-title":"Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"13","key":"10.1016\/j.bcp.2019.06.019_b0195","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1177\/1352458516684213","article-title":"miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands","volume":"23","author":"Quintana","year":"2017","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012132","article-title":"MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood","volume":"5","author":"Cox","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2019.06.019_b0205","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1007\/s11033-011-1441-7","article-title":"Circulating microRNAs involved in multiple sclerosis","volume":"39","author":"Siegel","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0210","doi-asserted-by":"crossref","first-page":"1286095","DOI":"10.1080\/20013078.2017.1286095","article-title":"Obstacles and opportunities in the functional analysis of extracellular vesicle RNA \u2013 an ISEV position paper","volume":"6","author":"Mateescu","year":"2017","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.bcp.2019.06.019_b0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fphys.2013.00163","article-title":"Extracellular membrane microvesicles and nanotubes in the brain: understanding their nature, their function in cell-to-cell communication, their role in transcellular spreading of pathological agents and their therapeutic potential","volume":"4","author":"Verderio","year":"2013","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0220","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ana.23627","article-title":"Myeloid microvesicles are a marker and therapeutic target for neuroinflammation","volume":"72","author":"Verderio","year":"2012","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0225","doi-asserted-by":"crossref","first-page":"14293","DOI":"10.1038\/s41598-017-14301-3","article-title":"Exosomal microRNA signatures in multiple sclerosis reflect disease status","volume":"7","author":"Ebrahimkhani","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0230","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-161179","article-title":"MicroRNA profile in patients with Alzheimer\u2019s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples","volume":"57","author":"Riancho","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163645","article-title":"Increased brain-specific MiR-9 and MiR-124 in the serum exosomes of acute ischemic stroke patients","volume":"11","author":"Ji","year":"2016","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-017-1803-x","article-title":"Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations","volume":"135","author":"Prada","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2019.06.019_b0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fimmu.2016.00129","article-title":"Is it worth considering circulating micrornas in multiple sclerosis?","volume":"7","author":"Jagot","year":"2016","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0250","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nn.3113","article-title":"An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration","volume":"15","author":"Lehmann","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0255","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12264-013-1419-7","article-title":"MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer's disease","volume":"30","author":"Tian","year":"2014","journal-title":"Neurosci. Bull."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1248\/bpb.b16-00898","article-title":"The anti-dementia effects of donepezil involve miR-206-3p in the hippocampus and cortex","volume":"40","author":"Wang","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2019.06.019_b0265","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopha.2017.05.060","article-title":"Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer\u2019s disease via modulating the expression of miR-106b","volume":"92","author":"Huang","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bcp.2019.06.019_b0270","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1212\/WNL.0000000000001258","article-title":"Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD","volume":"84","author":"Serafin","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2019.06.019_b0275","first-page":"1","article-title":"Differential expression of miRNA 155 and miRNA 146a in Parkinson\u2019s disease patients","volume":"13","author":"Caggiu","year":"2018","journal-title":"eNeurol. Sci."},{"key":"10.1016\/j.bcp.2019.06.019_b0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2016.11.002","article-title":"Potent anti-seizure effects of locked nucleic acid antagomirs targeting miR-134 in multiple mouse and rat models of epilepsy","volume":"6","author":"Reschke","year":"2017","journal-title":"Mol. Ther. Nucleic acids"},{"issue":"42","key":"10.1016\/j.bcp.2019.06.019_b0285","doi-asserted-by":"crossref","first-page":"72748","DOI":"10.18632\/oncotarget.20292","article-title":"MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0290","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2174\/1871527314666150317225945","article-title":"Dynamic expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the rat pilocarpine model and temporal lobe epilepsy patients","volume":"14","author":"Alsharafi","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0295","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11064-017-2453-z","article-title":"2R,4R-APDC, a metabotropic glutamate receptor agonist, reduced neuronal apoptosis by upregulating microRNA-128 in a rat model after seizures","volume":"43","author":"Feng","year":"2018","journal-title":"Neurochem. Res."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0300","doi-asserted-by":"crossref","first-page":"16087","DOI":"10.3390\/ijms140816087","article-title":"MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients","volume":"14","author":"Hecker","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0305","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12031-016-0851-3","article-title":"miR-145 and miR20a-5p potentially mediate pleiotropic effects of interferon-beta through mitogen-activated protein kinase signaling pathway in multiple sclerosis patients","volume":"61","author":"Ehtesham","year":"2017","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbadis.2017.09.024","article-title":"Human miR-26a-5p regulates the glutamate transporter SLC1A1 (EAAT3) expression. Relevance in multiple sclerosis","volume":"1864","author":"Potenza","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024604","article-title":"Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis","volume":"6","author":"Waschbisch","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.bcp.2019.06.019_b0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2016.08.017","article-title":"Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis","volume":"299","author":"Fenoglio","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0325","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","article-title":"Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects","volume":"144","author":"Sievers","year":"2012","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0330","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/acn3.152","article-title":"Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b","volume":"2","author":"Ingwersen","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2019.06.019_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157153","article-title":"Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients","volume":"11","author":"Mameli","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.bcp.2019.06.019_b0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-981-10-5987-2_5","article-title":"miR-155 dysregulation and therapeutic intervention in multiple sclerosis","volume":"1024","author":"McCoy","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acn3.270","article-title":"Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis","volume":"3","author":"Michell-Robinson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0350","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11481-015-9630-0","article-title":"Targeted stage-specific inflammatory microRNA profiling in urine during disease progression in experimental autoimmune encephalomyelitis: markers of disease progression and drug response","volume":"11","author":"Singh","year":"2016","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0355","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1096\/fj.201701533R","article-title":"Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients","volume":"32","author":"Manna","year":"2018","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.bcp.2019.06.019_b0360","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrneurol.2009.139","article-title":"Predicting responders to therapies for multiple sclerosis","volume":"5","author":"Rio","year":"2009","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.bcp.2019.06.019_b0365","doi-asserted-by":"crossref","first-page":"8914","DOI":"10.18632\/oncotarget.3563","article-title":"MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2","volume":"6","author":"Liao","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/now129","article-title":"miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas","volume":"19","author":"Li","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2019.06.019_b0375","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1007\/s10072-008-0941-2","article-title":"Interferon-beta responders and non-responders. A biological approach","volume":"29","author":"Bertolotto","year":"2008","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.019_b0380","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12031-019-01294-z","article-title":"Expression profile of selected microRNAs in the peripheral blood of multiple sclerosis patients: a multivariate statistical analysis with ROC curve to find new biomarkers for fingolimod","volume":"68","author":"Eftekharian","year":"2019","journal-title":"J. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0385","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Disc."},{"issue":"7","key":"10.1016\/j.bcp.2019.06.019_b0390","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/0271678X18773871","article-title":"MicroRNA-based therapeutics in central nervous system injuries","volume":"38","author":"Sun","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"5740","key":"10.1016\/j.bcp.2019.06.019_b0395","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0400","first-page":"878","article-title":"HCV infection and miravirsen","volume":"369","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.06.019_b0405","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.18632\/oncotarget.2779","article-title":"The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0415","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1139\/cjpp-2016-0248","article-title":"miR-29b promotes skin wound healing and reduces excessive scar formation by inhibition of the TGF-beta1\/Smad\/CTGF signaling pathway","volume":"95","author":"Guo","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Gallant-Behm","year":"2018","journal-title":"Wound Repair Regen."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0425","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1409","article-title":"Current progress on microRNAs-based therapeutics in neurodegenerative diseases","volume":"8","author":"Pereira","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.bcp.2019.06.019_b0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral vectors for therapy of neurologic diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.bcp.2019.06.019_b0435","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm.2791","article-title":"Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2","volume":"18","author":"Miyazaki","year":"2012","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0440","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.019_b0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202590","article-title":"Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis","volume":"13","author":"Laso-Garcia","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2019.06.019_b0450","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/stem.1409","article-title":"MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles","volume":"31","author":"Xin","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.bcp.2019.06.019_b0455","doi-asserted-by":"crossref","first-page":"31027","DOI":"10.3402\/jev.v5.31027","article-title":"A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery","volume":"5","author":"Hung","year":"2016","journal-title":"J. Extracell. Vesicles"},{"issue":"3","key":"10.1016\/j.bcp.2019.06.019_b0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-019-0223-5","article-title":"Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking","volume":"51","author":"Murphy","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0465","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5483\/BMBRep.2018.51.8.105","article-title":"Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep."},{"key":"10.1016\/j.bcp.2019.06.019_b0470","doi-asserted-by":"crossref","first-page":"30087","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials \u2013 an ISEV position paper","volume":"4","author":"Lener","year":"2015","journal-title":"J. Extracell. Vesicles"},{"issue":"8","key":"10.1016\/j.bcp.2019.06.019_b0475","article-title":"Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy","volume":"6","author":"Di Rocco","year":"2017","journal-title":"Transl. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2019.06.019_b0480","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1074\/jbc.M112.410944","article-title":"Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1","volume":"288","author":"Morel","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.019_b0485","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.bcp.2019.06.019_b0490","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.019_b0495","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbiotec.2013.03.013","article-title":"Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection","volume":"165","author":"Takahashi","year":"2013","journal-title":"J. Biotechnol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.019_b0500","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/sctm.18-0162","article-title":"Intranasal administration of extracellular vesicles derived from human teeth stem cells improves motor symptoms and normalizes tyrosine hydroxylase expression in the substantia nigra and striatum of the 6-hydroxydopamine-treated rats","volume":"8","author":"Narbute","year":"2019","journal-title":"Stem Cells Transl. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:06:43Z","timestamp":1757768803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":100,"alternative-id":["S0006295219302473"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNAs change the games in central nervous system pharmacology","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}